GW touts positive survival benefit in small brain cancer study; Ablynx files for ultra-rare disease drug OK
• GW Pharma is touting claims that a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) produced positive survival benefits in a small study of 21 patients with recurrent glioblastoma multiforme, a common form of brain cancer. The drug arm had an 83 percent one year survival rate compared with 53 percent for patients in the placebo group. Drawing a direct link between the drug and survival in such a small group, though, is difficult to do. The company is now exploring a pivotal study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.